Introduction
The homing of immune effector cells to a tumor site is a key process in the development of antitumor immune response. This process closely depends on the coordinated expression of cell adhesion molecules and chemokines on the surface of vascular endothelium. The in vivo studies using genetically engineered ICAM-1 and selectin-deficient mice have recently established that these molecules are essential for the recruitment of leukocytes to inflammatory [1] [2] [3] and tumor sites. 4 Indeed, genetic ablation of ICAM-1 favors the development of liver metastasis induced upon injection of B16 melanoma cells. 4 The implication of ICAM-1 in liver tumors is also supported by studies showing that high concentrations of soluble ICAM-1 that can inhibit interaction between tumor cells and immune effector cells, were observed in hepatocellular carcinoma models. 5, 6 The increased susceptibility of ICAM-1-deficient mice, or normal mice treated with ICAM-1-specific antibodies, to liver metastasis is attributed to inefficient homing of immune cells to infiltrate the tumor, 7, 8 terized for their antitumor activity in various experimental models of liver metastases. [9] [10] [11] [12] Neutrophils (PMN) expressing both ICAM-1 counter-receptors, MAC-1 and LFA-1, may also play a key role in the antitumor response. Not only are they capable of cytolytic activity against various tumor cells, [13] [14] [15] but they could also be involved in the destruction of tumor vessels, as shown in a recent study using an experimental model of metastasizing mammary adenocarcinoma. 16 Moreover, leukocyte elastase and MMP-9, two extracellular proteases secreted by PMN, have been shown to respectively release from precursor molecules angiostatin and endostatin, both of which are potent inhibitors of angiogenesis. 17, 18 Therefore, the induction of adhesion molecule expression on vascular endothelium that could attract immune effector cells in the organs could be an important strategy for cancer immunotherapy. Intravenous injections of cytokines, such as TNF-␣, that up-regulate the expression of ICAM-1 on the surface of endothelial cells, has been considered to increase the recruitment of immune cells to tumor sites. 19 Cytokine treatments, however, require a continuous injection of inflammatory cytokines, which is associated with significant side-effects. [20] [21] [22] Alternative strategies have been thus suggested for attracting immune cells to the local site of tumor, for example, by using local injections directly in solid tumors of one or more DNA vectors encoding inflammatory mediators, such as IL-2, MIP-3 and IL-7. [23] [24] [25] Although this strategy has the advantage of directing the homing of immune cells to a specific site, such injection in liver cancer is technically challenging. Another way to attract non-activated immune cells is to use transgenically expressed adhesion molecules responsible for leukocyte recruitment, which will not provoke nonspecific inflammatory cascade observed in the case of chemokine treatment.
We have recently demonstrated that a non-viral DNA carrier (P123PEI) comprising polyethyleneimine (PEI) grafted with polyoxyethylene-polypropylene block copolymer, Pluronic P123, provides plasmid DNA with a strong shift in biodistribution towards the liver and can be used for selective transgene expression in this organ. 26 In the present work, we have used P123PEI to selectively deliver ICAM-1-encoding plasmid in the liver of ICAM-1-deficient mice and to express functionally active ICAM-1 capable of inducing organ-specific infiltration of leukocytes.
Results

ICAM-1 expression in the liver of ICAM-1-deficient transgenic mice
The extracellular moiety of the common form of ICAM-1 consists of five immunoglobulin-like domains, the first and third of which mediate adhesion to LFA-1 and MAC-1, respectively. The use of genetically engineered ICAM-1-deficient mice carrying a mutation in exon 5 (encoding the fourth domain) has been extremely valuable in examining the role of ICAM-1 in inflammatory processes. 1 These ICAM-1-deficient mice ICAM1 Tm1Bay (Tm1Bay) exhibit abnormalities in inflammatory response, including impaired neutrophil emigration in chemically induced peritonitis and decreased contact hypersensitivity. 1 We have used the Tm1Bay mouse model to reconstitute the functionally active common form of ICAM-1 by injecting i.v. ICAM-1-encoding plasmid formulated with P123PEI.
Although ICAM-1-deficient mice do not express the common form of ICAM-1, they could still express aberrant mRNA products that could generate ICAM-1 isoforms, as shown by King et al. 27 To discriminate between the endogenous and transgenic full-size ICAM-1 mRNAs, two sets of PCR primers were designed, the first set amplifying the region between exon 2 and exon 5, and the second one -the region between exon 2 and exon 4 ( Figure 1a ). The first PCR product of 897 bp could only be of transgenic origin since the exon 5 region of ICAM-1 gene is disrupted in Tm1Bay mice, while the other PCR product (550 bp) could originate from both endogenous and transgenic mRNAs.
In the first series of experiments, we measured the expression of ICAM-1 transgene at the mRNA level in the liver and kidney (Figure 1b and c, respectively). As expected, both RT-PCR products were detected in the liver and kidneys of control C57BL/6 mice, while only the small RT-PCR product was obtained from untreated Tm1Bay mouse tissues. When Tm1Bay mice were injected with various doses of P123PEI-pICAM-1 formulation (25, 50 and 100 g of the plasmid per animal), the RT-PCR analysis of liver tissues ( Figure 1b) showed a dose-dependent expression of the common form of ICAM-1 mRNA (large RT-PCR product). Transgene ICAM-1 expression was also detected in kidneys ( Figure  1c ), but at a much lower level than that observed in the liver even at a dose of 100 g, which is consistent with previous results using the luciferase assay. 26 More detailed data on the organ distribution of a P123PEI-DNA complex was recently reported. 26 Briefly, P123-PEI carrier enhances accumulation of DNA in liver and, to a lesser degree, in spleen and heart, while it significantly reduces DNA accumulation in lungs. The large RT-PCR product was observed neither in liver nor kidney of Tm1Bay mice injected with non-formulated pICAM-1, nor in mice injected with the formulated pAPRM9 control plasmid (Figure 1b and c) . No amplification products were detected by PCR analysis without prior reverse transcription of any purified total mRNA indicating that the PCR products detected in mice injected with formulated pICAM-1 originated from ICAM-1-specific mRNA, rather than from the injected plasmid DNA (data not shown). These data indicate that plasmid DNA conjugated with P123PEI carrier is transcribed in a dosedependent manner in the liver upon a single i.v. injection.
Protein expression of ICAM-1 in the liver of Tm1Bay mice
To establish whether ICAM-1 mRNA was translated into protein, the expression of the transgene was studied by immunohistochemistry staining on frozen sections of liver using ICAM-1-specific YN1 monoclonal antibody. 28 In normal C57BL/6 mice, ICAM-1 expression is mainly located on capillaries and in sinusoidal areas of the liver ( Figure 2 ). No detectable expression of ICAM-1 was found in the liver of Tm1Bay mice. However, in Tm1Bay mice injected with P123PEI-formulated pICAM-1 plasmid, we found a substantial expression of ICAM-1 that was distributed throughout the sinusoidal area of the tissue, as no significant expression of ICAM-1 in larger capillaries was found ( Figure 2 ). The level of ICAM-1 expression is increased proportionally to the increase of the DNA dose. The animals treated with pAPRM9 control plasmid formulated with P123PEI showed no ICAM-1-positive staining. At 24 h after injection, no detectable signs of necrosis or hepatic injury were found in tissue sections for either dose (see Figure 2) .
Functional reconstitution of ICAM-1 in the liver of Tm1Bay mice injected with P123PEI-formulated pICAM-1
Neutrophil recruitment in the liver and other organs is mediated by ICAM-1 expression via interaction with MAC-1 and/or LFA-1.
1,2 To analyze the functional activity of the transgenically expressed common form of ICAM-1 in Tm1Bay mice, we investigated whether its expression could trigger neutrophil invasion. Polymorphonuclear cell infiltration was analyzed by staining liver sections with mAb against Ly-6G (Gr-1) antigen, a specific cellular marker for neutrophils in peripheral organs. 29, 30 As shown in Figure 2 , the liver sections of untreated C57BL/6 and Tm1Bay mice contained a small number of single positive cells randomly distributed throughout the tissue. In contrast, the liver sections of Tm1Bay mice treated with P123PEI-formulated pICAM-1 plasmid showed extensive invasion and clustering of neutrophils ( Figure 2 ). Location of blood vessels is indicated on the figures to simplify visualization of co-localiz- ation of ICAM-1 and Gr-1 expression. No such invasion was observed when P123PEI-formulated pAPRM9 control plasmid was used (Figure 2 ). The analysis of kidney tissues that were used as a control organ did not show any neutrophil infiltration in all groups of animals. No significant increase in the infiltration of MHC class 2 expressing cells (dendritic cells, monocytes) was noted in liver or kidney of mice injected with transgene ICAM-1 expression vector, when compared with non-injected mice (data not shown).
We have stained liver tissue sections of pICAM-1 formulation injected mice with an antibody against MHC class 2 (I-A b MHC class II, clone KH74, BD PharMingen, San Diego, CA, USA) and found no significant increase in the number of macrophages/dentritic cells compared with control untreated mice (data not shown).
Gene Therapy
Discussion
Organ-specific expression of transgenic ICAM-1 for inducing leukocyte recruitment could be potentially used as an immunotherapy tool for specific liver pathologies, such as hepatocellular cancer and some viral diseases. Polyethyleneimine (PEI) is a cationic polymer that provides effective gene expression in many in vitro settings and in vivo, when administered locally. However, similarly to cationic liposomes, PEI-DNA complexes tend to spontaneously aggregate and accumulate in lungs upon systemic administration, which often leads to microembolisms in capillaries and related acute toxicity, and also significantly reduces bioavailability of DNA to tissues other than lung. In addition, strong hemolytic toxicity of PEI and some other cationic polymers have been reported
Figure 2 Immunohistochemical analysis of ICAM-1 expression (left panels) and Ly-6G (Gr-1) positive cells (right panels) in the liver. ICAM-1 expression was detected by staining of the sections with ICAM-1-specific YN1/1.7.4 monoclonal antibody. ICAM-1 expressing cells in normal C57BL/6 liver (a) were located on perivascular and sinusoid capillaries. No detectable expression of ICAM-1 was observed in Tm1Bay mice (b). The injection of Tm1Bay mice with pICAM-1 formulated with P123PEI resulted in expression of ICAM-1 throughout the tissue, although no expression was detectable on the major capillaries (c). No ICAM-1 expression was observed in the liver of Tm1Bay mouse injected with 100 g of formulated control pAPRM9 plasmid (d). Normal livers of C56BL/6 and Tm1Bay mice both contained very few neutrophils randomly located throughout the tissue (e and f). Upon injection of Tm1Bay mice with formulated pICAM-1, massive neutrophil infiltration and aggregation could be observed throughout the tissue 24 h after injection (panel g, dose of 50 g of plasmid DNA shown). Mice injected with 100 g of formulated pAPRM9 control plasmid had no increase in neutrophil counts in the liver (h). Tissue sections were produced in series and were counterstained by hematoxylin. The results shown are representative of three independent stainings. Blood vessels (bv) have been indicated to indicate to simplify visualization of co-localization of ICAM-1 and Gr-1 expression.
as a dose-limiting factor for their systemic administration. 31 Biodistribution of non-viral systems could be improved by introducing targeting elements capable of directing DNA to target tissues. For instance, folate receptor, integrins, growth factor receptors, and other cell surface molecules have been successfully used as targets for non-viral gene delivery. [32] [33] [34] [35] [36] However, the use of such targeting strategy could induce secondary effects related to biological activity of the targeting moiety, which may counterbalance the beneficial effect of gene therapy. Moreover, a considerable increase in cost is associated with manufacturing of such targeted carriers. P123PEI, obtained by grafting linear polyethyleneimine with Pluronic P123, showed its ability to bypass the filtering effect of lung capillaries, thus allowing a substantial accumulation of the transgene plasmid in the liver. 26 In the present study, we have achieved a significant expression of ICAM-1 in the liver of ICAM-1 negative transgenic mice using a single i.v. injection of ICAM-1-encoding plasmid formulated with P123PEI. The analysis of ICAM-1/␤-actin ratios revealed a dose-dependent increase in the mRNA expression in the liver upon injection of DNA doses ranging from 25 to 100 g. The histological study has demonstrated that the ICAM-1 expression in the liver was significantly higher in the regions containing smaller sinusoidal capillaries compared with ICAM-1 expression pattern in normal mice. Furthermore, the expression level that we achieved using the P123PEI-formulated pICAM-1 was sufficient to induce massive infiltration of Ly-6G-positive leukocytes under normal physiological conditions, while such an infiltration usually occurs during an inflammation process associated with a considerable increase in proinflammatory cytokine expression. The homing of leukocytes to target organs during inflammation is a multiplestep process involving inflammatory mediators, such as chemokines, and de novo expression of a specific repertoire of adhesion molecules on vascular endothelium in response to increasing levels of TNF-␣ and/or IL-1 secreted by activated macrophages. 37 Several studies have shown that by reducing ICAM-1-dependent intercellular adhesion with specific antibodies 38, 39 or antisense oligonucleotides, [40] [41] [42] , it is possible to drastically reduce the inflammatory response. It is not that obvious, however, that one can induce or even enhance leukocyte recruitment by increasing ICAM-1 expression since many other cell surface and secreted molecules are involved in this process. For example, under normal physiological conditions, the expression level of ICAM-1 alone is not sufficient to recruit leukocytes into tissues. The infiltration observed in our case in response to ICAM-1 expression could be explained by two possibilities. Firstly, a high level of ICAM-1 expression achieved using pICAM-1 plasmid could bypass the endothelium activation step usually required to induce leukocyte extravasation, which includes expression of Selectins and ICAM-1, followed by activation of counter-receptors such as LFA-1. Secondly, the pattern of ICAM-1 expression obtained by using P123PEI as a carrier was more favorable for recruitment of leukocytes. As shown before, 43 the ICAM-1 pattern of expression in the liver of normal mice is usually restricted to endothelial cells in the portal vein and sinusoidal lining cells, including parenchymal cells, while in our experiment, ICAM-1 is expressed in a specific compartment in the liver. No neutrophil invasion was observed using a control plasmid, suggesting that ICAM-1 transgene protein product, rather than the carrier-DNA complex, was responsible for neutrophil invasion.
Truncated ICAM-1 is known to be expressed in ICAM-1-deficient mice in soluble form. 44 In our experiments, we did not see any significant increase in the soluble ICAM-1 levels upon administration of either formulated or non-formulated plasmid, suggesting that transgenic ICAM-1 is not shed from the membrane.
The enhanced expression of ICAM-1 in MCA-105, murine fibrosarcoma cell line, has been shown to reduce its tumor growth rate. 45 Similarly, the expression of ICAM-1 on rat hepatocellular carcinoma and human colorectal tumor cells has been shown to abrogate their tumorigenicity and induce anti-tumor immunity by the host. 46 Since ICAM-1 has been shown to act as an accessory molecule during antigen presentation, 47, 48 it is interesting to suggest that liver-specific expression of transgenic ICAM-1 could increase presentation of tumorspecific antigens in hepatocellular tumors.
In conclusion, our study has shown that transgenic expression of ICAM-1 in the liver using PEI grafted with Pluronic P123 could help the treatment of hepatic disorders by favoring recruitment of immune effector cells. Such strategy could also be used in combination with other approaches that are currently employed to attract immune cells, or that are designed to increase the antitumor activity of these cells.
Materials and methods
P123PEI synthesis
P123PEI block copolymer was prepared as previously described. 26 Briefly, 0.5 mmol of 1,1'-carbonyl-diimidazole-activated P123 (BASF, Parsipany, NJ, USA) was mixed with 2.5 mmol of PEI, 2 kDa (Sigma-Aldrich Chemical, St Louis, MO, USA) in 30 ml of 0.2 M carbonate buffer, pH 8.0. After 24 h, the reaction mixture was dialyzed twice against 50% ethanol using Membra-Cel MD-25-03.5 (Applied Technologies, Chicago, IL, USA) and then lyophilized.
DNA preparations (pAPRM9 and pICAM-1)
A 2.0 kb cDNA encoding the common form of murine ICAM-1 was inserted into pAPRM9 plasmid (5.3 kb) resulting in the pICAM-1 plasmid (7.3 kb). The pAPRM9 plasmid without an insert was used as control. All plasmids were expanded in DH5␣ E. coli and purified using the endotoxin-free plasmid Giga-prep kits according to the supplier's protocol (Qiagen, Valencia, CA, USA). The concentration of purified plasmid DNA was assessed by spectrophotometric analysis at 260 and 280 nm, as well as by electrophoresis in 1% agarose gel. The purified plasmids were resuspended in sterile saline buffer (Gibco-BRL, Burlington, ON, Canada) and frozen in aliquots at a concentration of 5 mg/ml.
Plasmid formulations
Plasmid DNAs (5 mg/ml) were mixed with copolymer P123PEI (100 g/ml) at a nitrogen-phosphate (N:P) ratio of 10:1, and the DNA concentration was adjusted to 1 mg/ml in PBS. The mixture was incubated for 30 min at room temperature before the injection.
Mice
C57BL/6 and ICAM-1-deficient mice (ICAM1
Tm1Bay
) were originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA). The mice colonies were maintained in the special pathogen-free animal facility at the INRSInstitut Armand-Frappier according to the institutional guidelines.
Gene Therapy
In vivo experiments
To test the expression of ICAM-1 transgene, male (6-8 weeks old) Tm1Bay mice were injected i.v. into the tail vein with a single dose of either 25, 50 or 100 g of pICAM-1 formulated with P123PEI or, with 100 g of pAPRM9 formulation. The animals were killed 24 h after injection, and the liver and kidneys were collected for RT-PCR analysis. Liver tissues were also collected for further immunohistochemistry analysis.
RT and PCR conditions for ICAM-1 analysis
Trizol reagent (Gibco-BRL) was used to purify total RNA from the liver or kidney tissues. Reverse-transcription (RT) reactions were carried out with 5 g of total RNA using Superscript II reverse transcriptase (Gibco-BRL) according to the manufacturer's instructions. PCR was carried out from 500 ng of cDNA using murine ICAM-1-specific primers that amplify a segment from exon 2 with the upstream primer E2S-5'-TTT GAG CTG AGC GAG ATC GGG-3' to exon 4 with the downstream primer E4AS-5'CTC CCA GCT CCA GGT ATA TCC GAG-3'. Since the genomic ICAM-1 gene of Tm1Bay mice was disrupted by inserting a Neo cassette into the exon 5 sequence, the second antisense primer, E5AS-5'-GGC AGA GCA AAA GAA GCT TCG, was designed to hybridize transgenic exon 5 mRNA. As an internal control, a fragment of ␤-actin mRNA was amplified by the upstream primer B1S-5'-CAT GGA TGA CGA TAT CGC TGC GC-3' and the downstream primer B2AS-5'-GCT GTC GCC ACG CTC GGT CAG GAT C-3'. The PCR conditions to amplify ICAM-1 cDNA fragments containing exon 2 to exon 4 or exon 2 to exon 5 were: 94°C, 1 min, 61°C, 1 min, 72°C, 1 min × 27 cycles and 72°C, 3 min. ␤-Actin amplification was performed as described above, but with only 23 PCR cycles. The number of cycles was established to be in the logarithmic amplification phase, thus allowing comparative analysis of PCR amplifications. PCR fragments, 550 bp for E2S-E4AS, 897 bp for E2S-E5AS and 575 bp for ␤-actin, were visualized by electrophoresis in 1.5% agarose gel and stained by ethidium bromide (1 g/ml) for 10 min.
Immunohistochemistry analysis
To detect ICAM-1 protein expression, tissue sections of liver were stained using monoclonal antibody (mAb) against ICAM-1 (clone YN1/1.7.4 from ATCC, Manassas, VA, USA). YN1 antibody was purified from hybridoma culture supernatants by chromatography on protein GSepharose using a standard protocol (Pharmacia, Piscataway, NJ, USA). To detect neutrophil invasion in the liver, mAb against Ly-6G (Gr-1) (clone RB6-8C5 from BD Pharmingen) was used. Biotinylated antibody against MHC class 2 (I-A b MHC class II, clone KH74, BD PharMingen) was also tested in liver to detect CMH class II positive cells. Frozen sections of liver (5 m) were airdried, briefly fixed in acetone at room temperature, and allowed to react in a humid chamber with primary mAb (anti-ICAM-1, anti-Ly-6G, or anti-I-A b ) for 30 min, then rinsed with a PBS-Tween buffer (0,05% Tween 20) . The anti-ICAM-1 and anti-Ly-6G stained sections were then allowed to react with peroxidase-conjugated anti-rat igG+M (H+L) (Zymed, San Francisco, CA, USA) for 30 min, then rinsed in PBS-Tween. The anti-I-Ab sections were reacted with streptavidin-horseradish peroxidase (Sav-HRP) reagent (BD PharMingen) as described earlier.
The reaction was revealed by an incubation of 20 min with the substrate (AEC, an amino carbazole substrate kit from Zymed). After counterstaining with hematoxylin, the preparations were then mounted in buffered glycerol and sealed.
